My aunt has stage IV Breast cancer with metastases?

to her lungs, lymph nodes, bones and now (since today) spine. The doctors aren’t going to do any sort of chemo on her because they say the cancer is just too advanced. My mother won’t come to terms with the fact that her sister is dying and is grasping at all sorts of hollistic medicines to heal her even though she is so very ill. My question is … is this a stage of grief for the family to go through denile and search for alternative healing and someone please be honest with me … regarding time are we talking weeks, months or what?
My aunt doesn’t want any help. She want’s to be left alone but my mom, her sister, absolutely isn’t ready to give up and let her go.

Well, I would say it is very normal to look for more options or solutions at this point.
And since there is no real cure for cancer people don’t give up their hopes that something might heal a loved one.
What does your aunt say to this?
I hope she will be ok and can be helped.

Breast Cancer with Metastases to the Liver, Lung and Bones

Development of synthetic extracellular matrix xenograft models for evaluation of lysophosphatidic acid antagonists. $49.99 Alpha-halomethylene phosphonate analogues of lysophosphatidic acid (LPA) are potent pan-LPA receptor antagonists and inhibitors of lysophospholipase D (lysoPLD, also autotoxin, ATX). Through G-protein-coupled receptors (GPCRs), LPA was found to promote cell proliferation, invasion, and angiogenesis. The production of LPA by ATX is also linked to enhanced invasion and metastasis. Thus, LPA antagonists with ATX inhibitory properties have significant potential as signal transduction modifiers (STMs) in cancer therapy. Herein, we developed various mouse cancer xenograft models addressing different aspects in cancer research. The engineered tumor xenograft models were generated using an in situ cross-linkable synthetic extracellular matrix (sECM) as cell delivery carrier. In vitro wound healing assays and cell invasion assays in this work showed that treatment of human breast cancer cells MDA-MB-231 and nonsmall cell lung cancer cells A549 with diastereomeric LPA antagonists 1a and 1b significantly inhibited cell proliferation, invasion and migration. The established xenograft model was applied, and hydrogel was seeded with MB-231 or A549 cells, and injected subcutaneously into nude mice. Once reaching desired tumor volume, animals were treated with vehicle alone or 3 mg/kg of the 1a and 1b for 2 weeks. Animals treated with the 1a and 1b developed tumors of significantly smaller volume compared with those in the control. Immunohistochemical analysis revealed the ability of the 1a and 1b to inhibit tumor cell angiogenesis. To further depict the effects of LPA antagonists on angiogenesis, we developed a plug model using the hydrogel with heparin-DTPH and growth factors. Blood vessels were calculated and hemoglobin (Hb) content was measured for the capability of angiogenesis inhibition. Finally, we described the successful use of mesenchymal stem cells (MSCs) to allow tumor growth in immunocompetent C3H mice. This overcomes the inherent weakness of immunodeficient animal

Development of synthetic extracellular matrix xenograft models for evaluation of lysophosphatidic acid antagonists. $69 Alpha-halomethylene phosphonate analogues of lysophosphatidic acid (LPA) are potent pan-LPA receptor antagonists and inhibitors of lysophospholipase D (lysoPLD, also autotoxin, ATX). Through G-protein-coupled receptors (GPCRs), LPA was found to promote cell proliferation, invasion, and angiogenesis. The production of LPA by ATX is also linked to enhanced invasion and metastasis. Thus, LPA antagonists with ATX inhibitory properties have significant potential as signal transduction modifiers (STMs) in cancer therapy. Herein, we developed various mouse cancer xenograft models addressing different aspects in cancer research. The engineered tumor xenograft models were generated using an in situ cross-linkable synthetic extracellular matrix (sECM) as cell delivery carrier. In vitro wound healing assays and cell invasion assays in this work showed that treatment of human breast cancer cells MDA-MB-231 and nonsmall cell lung cancer cells A549 with diastereomeric LPA antagonists 1a and 1b significantly inhibited cell proliferation, invasion and migration. The established xenograft model was applied, and hydrogel was seeded with MB-231 or A549 cells, and injected subcutaneously into nude mice. Once reaching desired tumor volume, animals were treated with vehicle alone or 3 mg/kg of the 1a and 1b for 2 weeks. Animals treated with the 1a and 1b developed tumors of significantly smaller volume compared with those in the control. Immunohistochemical analysis revealed the ability of the 1a and 1b to inhibit tumor cell angiogenesis. To further depict the effects of LPA antagonists on angiogenesis, we developed a plug model using the hydrogel with heparin-DTPH and growth factors. Blood vessels were calculated and hemoglobin (Hb) content was measured for the capability of angiogenesis inhibition. Finally, we described the successful use of mesenchymal stem cells (MSCs) to allow tumor growth in immunocompetent C3H mice. This overcomes the inherent weakness of immunodeficient animal

The Metastasis Suppressor $77 Ndrg-1 has been found to function as a metastasis suppressor in prostate, pancreatic, breast and other cancers. However, the molecular function of this elusive protein remains unknown. The aim of this study was to examine the function of Ndrg-1 in different cancer cells including prostate, lung and colon cancer. These studies reveal, for the first time, novel Ndrg-1 gene targets including Ccl2, Hod3, Thtpa, Fmo3 and VEGF. Ndrg-1 was also found to affect prostate cancer cell adhesion and proliferation. Furthermore, the ability of novel anti-cancer agents, the iron chelators, to up-regulate Ndrg-1 was also explored. Our results indicate that iron chelators are a promising new treatment strategy for cancer, partly due to their ability to increase cellular levels of this important metastasis suppressor protein.